From greentech to biotech, check out which industries Seattle-based tech companies are innovating after last week’s growth moves. This is is the Built In Seattle Weekly Refresh.
Mozart Therapeutics pulled in $25M. Biotech company Mozart develops therapies for autoimmune and inflammatory diseases. The company announced an extension to its Series A round, closing out the raise at $80 million. The money will help Mozart advance MTX-101, its autoimmune checkpoint inhibitor, into in-human clinical trials. [PR Newswire]
Seattle Tech Quote of the Week
“We bring the much needed CRM simplicity U.S. customers need to easily onboard users with effective and personalized marketing engagements that deliver a rapid return on value in just a few clicks. Brevo’s European heritage brings a refreshing mindset to both the B2C and B2B North American market with a highly efficient solution that adheres to the ever-changing data privacy, and security regulations.” — Isabelle Guis, CEO North America and Global CMO at Brevo
Brevo hired new executives. Formerly known as Sendinblue, Brevo, a customer relationship management solution, announced the addition of a new c-suite member. Joining the company from Salesforce is Isabelle Guis as Brevo’s CEO of North America and Global CMO. Additionally, the company appointed veteran sales executive Julien Cros as its sales director of North America. [Brevo]
Nori pulled in $6.25M. Climate tech solution Nori sells carbon credits from sustainable farmers on the blockchain. The company announced a new funding round from M13, Toyota Ventures and other investors that brings its total capital raised to $17.25 million. This news follows the company’s partnership with agriculture company Bayer, which is providing carbon removal offsets to Nori’s platform. [GeekWire]
